Political Quotes

“This is an amendment to the bill, or the final amendment to the bill, which will not kill the bill or send it back to committee. If adopted, the bill will immediately proceed to final passage, as amended. And this amendment would offer a more targeted approach to improving the FDA's current expanded access program. In October, the Energy and Commerce Committee held a hearing on the widely opposed Senate right-to-try legislation. At that hearing, we heard concerns from FDA Commissioner Gottlieb and also from manufacturers, academic experts, and patient groups that S. 204 was legislation that would expose broad numbers of patients to harm, and sought to hamstrung the FDA's ability to oversee or engage in any meaningful way on the use of investigational treatments. Since that time, my colleagues on the other side of the aisle have drafted new legislation that maintains, in my opinion, the same harmful approach prohibiting FDA review of experimental treatments. The FDA is part of the process for a reason. It protects patients from potentially bad actors or from experimental treatments that might do more harm than good. So my motion to recommit, Mr. Speaker, abandons this harmful attempt to undermine the FDA's expanded access pathway and, instead, seeks to make two improvements that have been identified as meaningful by both manufacturers and patient groups.…”